Cadrenal Therapeutics, Inc.
CVKDHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Cadrenal Therapeutics, Inc. focuses on Biotechnology services and products. Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. With a market capitalization of $4.3M, it sits in micro-cap territory. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial.
Market Cap
$4.3M
Beta
1.84
P/E (TTM)
—
P/E (Fwd)
-0.35
EPS (TTM)
$-4.84
EPS (Fwd)
$-3.40
ROE
-275.2%
ROA
-125.9%
Cash
$2.4M
Total Debt
$0
Free CF
-$8.5M
52W Change
-90.8%
Annual Financials
Cash vs Debt
Where CVKD stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CVKD finished 70.58% below its 150-day moving average ($4.52) and 76.16% below its 200-day moving average ($5.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CVKD overbought or oversold?
At the September 3, 2026 close, CVKD's RSI(14) was 25.5, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cadrenal Therapeutics, Inc. reports $2.4M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$8.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -275.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.84 means CVKD is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cadrenal Therapeutics, Inc. and its sector.